secwatch.observer — SEC 8-K summary
======================================

Issuer:     Barinthus Biotherapeutics plc. (BRNS)
CIK:        0001828185
Form:       8-K
Filed at:   2026-07-02T20:05:21+00:00
Accession:  0001104659-26-080308
Event type: regulatory
Sentiment:  negative
Materiality: 0.70
Item codes: 5.07, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Barinthus Biotherapeutics gets Nasdaq extension to Dec 28, 2026; listing moved to Capital Market
--------------------------------------------------------------------------------

- Received 180-day extension from Nasdaq until Dec 28, 2026 to regain $1.00 minimum bid price for ADSs.
- ADS listing transferred from Nasdaq Global Market to Nasdaq Capital Market effective July 2, 2026.
- Company may consider reverse stock split to regain compliance; no assurance of success.
- If bid price does not close at $1.00 for 10 consecutive days by Dec 28, 2026, ADSs may be delisted.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1828185/000110465926080308/0001104659-26-080308-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1828185/000110465926080308/tm2619582d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-080308

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer